Abstract：
OBJECTIVE: The goal of this paper is to summarize the data pertaining to the use of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) for the prevention of cardiotoxicity in patients receiving anthracyclines for cancer treatment. We discuss the potential efficacy of this class of medications, incorporating insights from existing literature and ongoing studies.
RESULTS: SGLT2i are a class of medications which were initially developed for treatment of Type 2 diabetes and later extended to treat heart failure with reduced and preserved ejection fraction regardless of diabetes status. There remains a need for effective and safe treatments to preventing cardiotoxicity in anthracycline-treated patients. It has been proposed that SGLT2i may provide protection against the cardiotoxic effects of anthracyclines. Some of the proposed mechanisms include beneficial metabolic, neurohormonal, and hemodynamic effects, renal protection, as well as a decrease in inflammation, oxidative stress, apoptosis, mitochondrial dysfunction and ion homeostasis. There is emerging evidence from basic science and observational studies that SGLT2i may play a role in the prevention of chemotherapy-induced cardiotoxicity. Randomized controlled trials are needed to conclusively determine the role of SGLT2 inhibitors as a cardioprotective therapy in patients receiving anthracyclines for the treatment of cancer.
RESULTS: SGLT2i are a class of medications which were initially developed for treatment of Type 2 diabetes and later extended to treat heart failure with reduced and preserved ejection fraction regardless of diabetes status. There remains a need for effective and safe treatments to preventing cardiotoxicity in anthracycline-treated patients. It has been proposed that SGLT2i may provide protection against the cardiotoxic effects of anthracyclines. Some of the proposed mechanisms include beneficial metabolic, neurohormonal, and hemodynamic effects, renal protection, as well as a decrease in inflammation, oxidative stress, apoptosis, mitochondrial dysfunction and ion homeostasis. There is emerging evidence from basic science and observational studies that SGLT2i may play a role in the prevention of chemotherapy-induced cardiotoxicity. Randomized controlled trials are needed to conclusively determine the role of SGLT2 inhibitors as a cardioprotective therapy in patients receiving anthracyclines for the treatment of cancer.
摘要：
目的：本文的目的是总结有关使用钠-葡萄糖协同转运蛋白-2抑制剂（SGLT-2i）预防接受蒽环类药物治疗的癌症患者心脏毒性的数据。我们讨论这类药物的潜在疗效，结合现有文献和正在进行的研究的见解。
结果：SGLT2i是一类药物，最初开发用于治疗2型糖尿病，后来扩展用于治疗心力衰竭，无论糖尿病状态如何，射血分数降低和保留。仍然需要有效和安全的治疗方法来预防蒽环类药物治疗的患者的心脏毒性。已经提出SGLT2i可以提供针对蒽环类药物的心脏毒性作用的保护。一些提出的机制包括有益的代谢，神经激素，和血液动力学的影响，肾脏保护,以及炎症的减少，氧化应激，凋亡，线粒体功能障碍和离子稳态。来自基础科学和观察性研究的新证据表明，SGLT2i可能在预防化疗引起的心脏毒性中发挥作用。需要随机对照试验来最终确定SGLT2抑制剂在接受蒽环类药物治疗癌症的患者中作为心脏保护疗法的作用。
结果：SGLT2i是一类药物，最初开发用于治疗2型糖尿病，后来扩展用于治疗心力衰竭，无论糖尿病状态如何，射血分数降低和保留。仍然需要有效和安全的治疗方法来预防蒽环类药物治疗的患者的心脏毒性。已经提出SGLT2i可以提供针对蒽环类药物的心脏毒性作用的保护。一些提出的机制包括有益的代谢，神经激素，和血液动力学的影响，肾脏保护,以及炎症的减少，氧化应激，凋亡，线粒体功能障碍和离子稳态。来自基础科学和观察性研究的新证据表明，SGLT2i可能在预防化疗引起的心脏毒性中发挥作用。需要随机对照试验来最终确定SGLT2抑制剂在接受蒽环类药物治疗癌症的患者中作为心脏保护疗法的作用。
